In rectal cancer in patients receiving total neoadjuvant therapy of FOLFOX followed by 5FU-radiation, is there a role for additional adjuvant chemotherapy based on significant residual disease at time of surgery?

To my knowledge, there is no known role for additional adjuvant treatment in patients with rectal cancer who have received total neoadjuvant therapy with FOLFOX followed by chemoradiation or short-course radiation (SCRT). As of yet, no clinical trials address this situation. Furthermore, there is no known benefit to any rectal cancer adjuvant therapy that goes beyond FOLFOX + chemoradiation or SCRT, regardless of the order that therapy is delivered. Given the absence of data for benefit, I would...